Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety of topical 0.03% DSC127 Gel when used for one or more continuous
treatment periods on a chronic Wagner Grade 1 or 2 foot ulcer(target ulcer) or multiple
ulcers in diabetic subjects. The maximum duration of any treatment period is 24 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Derma Sciences, Inc. Integra LifeSciences Corporation